These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 7623530)

  • 41. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase.
    Moser M; Kohler B; Schmittner M; Bode C
    BioDrugs; 1998 Jun; 9(6):455-63. PubMed ID: 18020578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
    Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
    Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trials in thrombolytic therapy, Part 2: The open-artery hypothesis and RAPID-1 and RAPID-2.
    Lopez LM
    Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S27-30. PubMed ID: 9397235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction.
    El-Menyar AA; Altamimi OM; Gomaa MM; Dabdoob W; Abbas AA; Abdel Rahman MO; Bener A; Albinali HA
    Coron Artery Dis; 2006 Aug; 17(5):431-7. PubMed ID: 16845251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
    Martin U; Kaufmann B; Neugebauer G
    Clin Pharmacokinet; 1999 Apr; 36(4):265-76. PubMed ID: 10320949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
    Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
    Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD
    Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
    Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Increased efficacy of thrombolytic therapy in acute myocardial infarction by improved properties of new thrombolytic agents].
    Huber K
    Wien Klin Wochenschr; 2000 Sep; 112(17):742-8. PubMed ID: 11042902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction.
    Lancet; 1993 Sep; 342(8874):759-66. PubMed ID: 8103874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction.
    Tatu-Chiţoiu G; Teodorescu C; Dan M; Căpraru P; Guran M; Istrătescu O; Tatu-Chiţoiu A; Bumbu A; Dorobanţu M
    Rom J Intern Med; 2003; 41(4):395-408. PubMed ID: 15526522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Another coronary reperfusion regimen.
    Simoons ML
    Lancet; 1995 Aug; 346(8971):324-5. PubMed ID: 7623525
    [No Abstract]   [Full Text] [Related]  

  • 55. Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.
    Möckel M; Bocksch W; Strohm S; Kühnle Y; Vollert J; Nibbe L; Dietz R
    Int J Cardiol; 2005 Aug; 103(2):193-200. PubMed ID: 16080980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
    Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
    Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M
    Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular biology of plasminogen activators: what are the clinical implications of drug design?
    Smalling RW
    Am J Cardiol; 1996 Dec; 78(12A):2-7. PubMed ID: 8990404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
    Gillis JC; Wagstaff AJ; Goa KL
    Drugs; 1995 Jul; 50(1):102-36. PubMed ID: 7588083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.